Endocrine Pathology
Vaikuttavuuskerroin - Analyysi · Trendi · Sijoitus · Ennustus


New

Vaikuttavuuskerroin

2020-2021

3.943

24.5%

Vaikuttavuuskerroin Trend

Researchain
One-click to visualize your research performance

Researchain
One-click to visualize your research performance

Researchain
One-click to visualize your research performance

Researchain
One-click to visualize your research performance

Highly Cited Articles

Endocrine Pathology

High Impact Research Articles
Publication Title Author Listing
Publication Title Author Listing
· · ·
· · · · · ·
· · · · · · ·
· · · ·
· · · ·
· · ·
· · · · · · ·
· · · · · · · · ·
· · · · ·
· · · ·
· · · ·
· · · · · · · ·
· · · · ·
· · ·
· · · · · · · · · · · ·
· · ·
· · · · · · · · · · · ·
· · · · · · · · · · ·
· · · · · · · · ·
· · · · ·
· · · · · ·
· · · · · ·
· · · · · · ·
· · · · · · · · ·
· · · ·
· · · · · ·
· · · · · · ·
· · · · ·
· ·
· · · · ·
· · · · · · · ·
· · · · · · · · · · ·
· · · · · · ·
· · ·
· · · · · · · · · ·
· · · · · · · · ·
· · ·
· · · · ·
· · ·

Highly Cited Keywords

Endocrine Pathology

High Impact Research Keywords

Related Journals

Popular Journals

Endocrine Pathology

The 2020-2021 Vaikuttavuuskerroin of Endocrine Pathology is 3.943, which is just updated in 2021.

Endocrine Pathology Impact Factor
Highest IF
3.943
Highest Vaikuttavuuskerroin

The highest Vaikuttavuuskerroin of Endocrine Pathology is 3.943.

Lowest IF
1.358
Lowest Vaikuttavuuskerroin

The lowest Vaikuttavuuskerroin of Endocrine Pathology is 1.358.

Total Growth Rate
190.4%
IF Total Growth Rate

The total growth rate of Endocrine Pathology IF is 190.4%.

Annual Growth Rate
19.0%
IF Annual Growth Rate

The annual growth rate of Endocrine Pathology IF is 19.0%.

Vaikuttavuuskerroin Ranking

Subcategory Quartile Rank Percentile
Pathology and Forensic Medicine Q1 31/191

Pathology and Forensic Medicine 84%

Endocrinology, Diabetes and Metabolism Q2 56/219

Endocrinology, Diabetes and Metabolism 74%

Endocrinology Q2 42/117

Endocrinology 64%

Vaikuttavuuskerroin Ranking

· In the Pathology and Forensic Medicine research field, the Quartile of Endocrine Pathology is Q1. Endocrine Pathology has been ranked #31 over 191 related journals in the Pathology and Forensic Medicine research category. The ranking percentile of Endocrine Pathology is around 84% in the field of Pathology and Forensic Medicine.
· In the Endocrinology, Diabetes and Metabolism research field, the Quartile of Endocrine Pathology is Q2. Endocrine Pathology has been ranked #56 over 219 related journals in the Endocrinology, Diabetes and Metabolism research category. The ranking percentile of Endocrine Pathology is around 74% in the field of Endocrinology, Diabetes and Metabolism.
· In the Endocrinology research field, the Quartile of Endocrine Pathology is Q2. Endocrine Pathology has been ranked #42 over 117 related journals in the Endocrinology research category. The ranking percentile of Endocrine Pathology is around 64% in the field of Endocrinology.

Endocrine Pathology Impact Factor 2021-2022 Prediction

Endocrine Pathology Impact Factor Predition System

Endocrine Pathology Impact Factor Prediction System is now online. You can start share your valuable insights with the community.

Predict Check All Preditions
Total Publications
1302
Total Citations
21388

Annual Publication Volume

Annual Citation Record

International Collaboration Trend

Cited Documents Trend

Vaikuttavuuskerroin History

Year Vaikuttavuuskerroin
Year Vaikuttavuuskerroin
2020-2021 3.943
2019-2020 3.168
2018-2019 3.366
2017-2018 2.541
2016-2017 1.936
2015-2016 1.817
2014-2015 1.757
2013-2014 1.644
2012-2013 1.6
2011-2012 1.358
Vaikuttavuuskerroin History

· The 2020-2021 Vaikuttavuuskerroin of Endocrine Pathology is 3.943
· The 2019-2020 Vaikuttavuuskerroin of Endocrine Pathology is 3.168
· The 2018-2019 Vaikuttavuuskerroin of Endocrine Pathology is 3.366
· The 2017-2018 Vaikuttavuuskerroin of Endocrine Pathology is 2.541
· The 2016-2017 Vaikuttavuuskerroin of Endocrine Pathology is 1.936
· The 2015-2016 Vaikuttavuuskerroin of Endocrine Pathology is 1.817
· The 2014-2015 Vaikuttavuuskerroin of Endocrine Pathology is 1.757
· The 2013-2014 Vaikuttavuuskerroin of Endocrine Pathology is 1.644
· The 2012-2013 Vaikuttavuuskerroin of Endocrine Pathology is 1.6
· The 2011-2012 Vaikuttavuuskerroin of Endocrine Pathology is 1.358

Publications Cites Dataset

Year Publications Citations
Year Publications Citations
1990 26 2
1991 32 20
1992 28 35
1993 33 31
1994 31 40
1995 39 93
1996 36 100
1997 38 151
1998 44 169
1999 42 202
2000 39 215
2001 43 225
2002 43 235
2003 39 321
2004 40 452
2005 42 583
2006 45 706
2007 33 699
2008 41 805
2009 42 1052
2010 43 1294
2011 41 1099
2012 39 1205
2013 42 1221
2014 66 1388
2015 62 1484
2016 48 1415
2017 52 1484
2018 48 1310
2019 41 1380
2020 56 1825
2021 8 147
Publications Cites Dataset

· The Endocrine Pathology has published 26 reports and received 2 citations in 1990.
· The Endocrine Pathology has published 32 reports and received 20 citations in 1991.
· The Endocrine Pathology has published 28 reports and received 35 citations in 1992.
· The Endocrine Pathology has published 33 reports and received 31 citations in 1993.
· The Endocrine Pathology has published 31 reports and received 40 citations in 1994.
· The Endocrine Pathology has published 39 reports and received 93 citations in 1995.
· The Endocrine Pathology has published 36 reports and received 100 citations in 1996.
· The Endocrine Pathology has published 38 reports and received 151 citations in 1997.
· The Endocrine Pathology has published 44 reports and received 169 citations in 1998.
· The Endocrine Pathology has published 42 reports and received 202 citations in 1999.
· The Endocrine Pathology has published 39 reports and received 215 citations in 2000.
· The Endocrine Pathology has published 43 reports and received 225 citations in 2001.
· The Endocrine Pathology has published 43 reports and received 235 citations in 2002.
· The Endocrine Pathology has published 39 reports and received 321 citations in 2003.
· The Endocrine Pathology has published 40 reports and received 452 citations in 2004.
· The Endocrine Pathology has published 42 reports and received 583 citations in 2005.
· The Endocrine Pathology has published 45 reports and received 706 citations in 2006.
· The Endocrine Pathology has published 33 reports and received 699 citations in 2007.
· The Endocrine Pathology has published 41 reports and received 805 citations in 2008.
· The Endocrine Pathology has published 42 reports and received 1052 citations in 2009.
· The Endocrine Pathology has published 43 reports and received 1294 citations in 2010.
· The Endocrine Pathology has published 41 reports and received 1099 citations in 2011.
· The Endocrine Pathology has published 39 reports and received 1205 citations in 2012.
· The Endocrine Pathology has published 42 reports and received 1221 citations in 2013.
· The Endocrine Pathology has published 66 reports and received 1388 citations in 2014.
· The Endocrine Pathology has published 62 reports and received 1484 citations in 2015.
· The Endocrine Pathology has published 48 reports and received 1415 citations in 2016.
· The Endocrine Pathology has published 52 reports and received 1484 citations in 2017.
· The Endocrine Pathology has published 48 reports and received 1310 citations in 2018.
· The Endocrine Pathology has published 41 reports and received 1380 citations in 2019.
· The Endocrine Pathology has published 56 reports and received 1825 citations in 2020.
· The Endocrine Pathology has published 8 reports and received 147 citations in 2021.
· The total publications of Endocrine Pathology is 1302.
· The total citations of Endocrine Pathology is 21388.

Endocrine Pathology
Journal Profile
Endocrine Pathology | Academic Accelerator - About the Journal

About

Endocrine Pathology publishes original articles on clinical and basic aspects of endocrine disorders. Work with animals or in vitro techniques is acceptable if it is relevant to human normal or abnormal endocrinology. Manuscripts will be considered for publication in the form of original articles, case reports, clinical case presentations, reviews, and descriptions of techniques. Submission of a paper implies that it reports unpublished work, except in abstract form, and is not being submitted simultaneously to another publication. Accepted manuscripts become the sole property of Endocrine Pathology and may not be published elsewhere without written consent from the publisher. All articles are subject to review by experienced referees. The Editors and Editorial Board judge manuscripts suitable for publication, and decisions by the Editors are final. None

ISSN
1046-3976
ISSN

The ISSN of Endocrine Pathology is 1046-3976 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

ISSN (Online)
1559-0097
ISSN (Online)

The ISSN (Online) of Endocrine Pathology is 1559-0097 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

Publisher
Humana Press
Publisher

Endocrine Pathology is published by Humana Press .

Publication Frequency
Quarterly
Publication Frequency

Endocrine Pathology publishes reports Quarterly .

Coverage
1990 - Present
Coverage

The Publication History of Endocrine Pathology covers 1990 - Present .

Open Access
NO
Open Access

Publication Fee
Review
Publication Fee

Language
English
Language

The language of Endocrine Pathology is English .

Country/Region
United States
Country/Region

The publisher of Endocrine Pathology is Humana Press , which locates in United States .

What is Impact Factor?

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly average number of citations of articles published in the last two years in a given journal. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are often deemed to be more important, or carry more intrinsic prestige in their respective fields, than those with lower values.

Endocrine Pathology | Academic Accelerator - About the Impact Factor

Impact factor is commonly used to evaluate the relative importance of a journal within its field and to measure the frequency with which the “average article” in a journal has been cited in a particular time period. Journal which publishes more review articles will get highest IFs. Journals with higher IFs believed to be more important than those with lower ones. According to Eugene Garfield “impact simply reflects the ability of the journals and editors to attract the best paper available.” Journal which publishes more review articles will get maximum IFs. The Impact Factor of an academic journal is a scientometric Metric that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a Metric for the relative importance of a journal within its field; journals with higher Impact Factor are often deemed to be more important than those with lower ones. The Endocrine Pathology Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the Endocrine Pathology during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; they cannot be calculated until all of the 2020 publications have been processed by the indexing agency. New journals, which are indexed from their first published issue, will receive an impact factor after two years of indexing; in this case, the citations to the year prior to Volume 1, and the number of articles published in the year prior to Volume 1, are known zero values. Journals that are indexed starting with a volume other than the first volume will not get an impact factor until they have been indexed for three years. Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. In addition to the 2-year Impact Factor, the 3-year Impact Factor, 4-year Impact Factor, 5-year Impact Factor, Real-Time Impact Factor can provide further insights and factors into the impact of Endocrine Pathology.

History

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI). Impact factors are calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson ISI was sold to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.

Use

The impact factor is used to compare different journals within a certain field. The Web of Science indexes more than 11,500 science and social science journals. Journal impact factors are often used to evaluate the merit of individual articles and individual researchers. This use of impact factors was summarised by Hoeffel:

Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary.

Eugene Garfield

In brief, Impact factors may be used by:
  • Authors to decide where to submit an article for publication.
  • Libraries to make collection development decisions
  • Academic departments to assess academic productivity
  • Academic departments to make decisions on promotion and tenure.
As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Garfield agrees with Hoeffel,but warns about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Other things to consider about Impact Factors:
  • Many journals do not have an impact factor.
  • The impact factor cannot assess the quality of individual articles. Even if citations were evenly distributed among articles, the impact factor would only measure the interests of other researchers in an article, not its importance and usefulness.
  • Only research articles, technical notes and reviews are “citable” items. Editorials, letters, news items and meeting abstracts are “non-citable items”.
  • Only a small percentage of articles are highly cited and they are found in a small subset of journals. This small proportion accounts for a large percentage of citations.
  • Controversial papers, such as those based on fraudulent data, may be highly cited, distorting the impact factor of a journal.
  • Citation bias may exist. For example, English language resources may be favoured. Authors may cite their own work.
Moreover, informed and careful use of these impact data is essential, and should be based on a thorough understanding of the methodology used to generate impact factors. There are controversial aspects of using impact factors:
  • It is not clear whether the number of times a paper is cited measures its actual quality.
  • Some databases that calculate impact factors fail to incorporate publications including textbooks, handbooks and reference books.
  • Certain disciplines have low numbers of journals and usage. Therefore, one should only compare journals or researchers within the same discipline.
  • Review articles normally are cited more often and therefore can skew results.
  • Self-citing may also skew results.
  • Some resources used to calculate impact factors have inadequate international coverage.
  • Editorial policies can artificially inflate an impact factor.
Impact factors have often been used in advancement and tenure decision-making. Many recognize that this is a coarse tool for such important decisions, and that a multitude of factors should be taken into account in these deliberations. When considering the use of the impact factor (IF), keep these aspects in mind:
  • IF analysis is limited to citations from the journals indexed by the Web of Science/Web of Knowledge. Currently, the Web of Science indexes only 8621 journals across the full breadth of the sciences, and just 3121 in the social sciences.
  • A high IF/citation rate says nothing about the quality -- or even, validity -- of the references being cited. Notorious or even retracted articles often attract a lot of attention, hence a high number of citations. The notority related to the first publication on "cold fusion" is one such example.
  • Journals that publish more "review articles" are often found near the top of the rankings. While not known for publishing new, creative findings, these individual articles tend to be heavily cited.
  • The IF measures the average number of citations to articles in the journal -- given this, a small number of highly-cited articles will skew the figure.
  • It takes several years for new journals to be added to the list of titles indexed by the Web of Science/Web of Knowledge, so these newer titles will be under-represented.
  • It's alleged that journal editors have learned to "game" the system, encouraging authors to cite their works previously published in the same journal.
Comparing Journals Across Disciplines? Not a good idea! Using Impact Factors within a given discipline should only be done with great care, as described above. Using impact factor data to compare journals across disciplines is even more problematic. Here are some of the reasons:
  • Disciplines where older literature is still referenced, such as Chemistry and Mathematics, offer challenges to the methodolgy since older citations (older than two years) are not used to calculate the impact factor for a given journal. (Five-year impact factor analysis, which can be calculated using the Journal Citation Index database, helps smooth out this problem only to some degree.)
  • Different disciplines have different practices regarding tendency to cite larger numbers of references. Higher overall citation rates will bump upward impact factor measurements.
  • Where it's common for large numbers of authors to collaborate on a single paper, such as in Physics, the tendency of authors to cite themselves (and in this case, more authors) will result in increased citation rates.

Pros and Cons of the Impact Factor

Pros:

  • A vetted, established metric for measuring journal impact within a discipline.
  • Designed to eliminate bias based on journal size and frequency.
Cons:
  • Individual articles makes an uneven contribution to overall Impact Factor.
  • Impact Factor does not account for certain things, things like context (postive or negative citaion) and intentionality (self-citation).
  • The metric is proprietary to and bound by the contents of the Thomson Reuters database.
  • Citations, on which the Impact Factor is based, count for less than 1% of an article's overall use.

Criticism

Numerous critiques have been made regarding the use of impact factors. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on behavior of scholars, editors and other stakeholders. Others have made more general criticisms, arguing that emphasis on impact factor results from negative influence of neoliberal policies on academia claiming that what is needed is not just replacement of the impact factor with more sophisticated metrics for science publications but also discussion on the social value of research assessment and the growing precariousness of scientific careers in higher education.
Experts stress that there are limitations in using impact factors to evaluate a scholar's work. There are many reasons cited for not relying on impact factor alone to evaluate the output of a particular individual. Among these are the following:

  • A single factor is not sufficient for evaluating an author's work.
  • Journal values are meaningless unless compared within the same discipline. Impact factors vary among disciplines.
  • The impact factor was originally devised to show the impact of a specific journal, not a specific scholar. The quality and impact of the author's work may extend beyond the impact of a particular journal.
According to Jim Testa, a researcher for ThomsonReuters Scientific, the most widespread misuse of the Impact Factor is to evaluate the work of an individual author (instead of a journal). "To say that because a researcher is publishing in a certain journal, he or she is more influential or deserves more credit is not necessarily true. There are many other variables to consider." (interview 6/26/2008 in Thomson Reuters blog entry)


The current study was performed to find the effect of individual metals (cadmium and mercury), their co-administration, and the ameliorative effects of vitamin C on some of the parameters that indicate oxidative stress and thyroid dysfunction.

Toxicological effects of toxic metals (cadmium and mercury) on blood and the thyroid gland and pharmacological intervention by vitamin C in rabbits [10.1007/s11356-019-04886-9]


Small PTC (≤20 mm) and especially papillary thyroid microcarcinomas (PTMC ≤10 mm) are considered to be low-risk tumors but some cases are considerably more aggressive.

Invasiveness and Metastatic Aggressiveness in Small Differentiated Thyroid Cancers: Demography of Small Papillary Thyroid Carcinomas in the Swedish Population [10.1007/s00268-019-05312-4]


OBJECTIVE To investigate the signal amplitudes of transient evoked otoacoustic emissions (TEOAE) in neonates and infants diagnosed with congenital hypothyroidism (HC) and verify their association with clinical and laboratory aspects.

Study of cochlear function in neonates and infants with congenital hypothyroidism. [10.1016/J.IJPORL.2019.05.026]


The aim of this study was to assess the course of cortical bone dimensions in the hip by comparing patients with acromegaly and clinically nonfunctioning pituitary adenomas (NFPAs) at baseline and 1 year after pituitary surgery (1-year PO) in a longitudinal cohort study.

Hip structure analyses in acromegaly: Decrease of cortical bone thickness after treatment [10.1530/ENDOABS.63.GP111]


The aim of this study was to assess the course of cortical bone dimensions in the hip by comparing patients with acromegaly and clinically nonfunctioning pituitary adenomas (NFPAs) at baseline and 1 year after pituitary surgery (1-year PO) in a longitudinal cohort study.

Hip structure analyses in acromegaly: Decrease of cortical bone thickness after treatment [10.1530/ENDOABS.63.GP111]


The aim of this study was to assess the course of cortical bone dimensions in the hip by comparing patients with acromegaly and clinically nonfunctioning pituitary adenomas (NFPAs) at baseline and 1 year after pituitary surgery (1-year PO) in a longitudinal cohort study.

Hip structure analyses in acromegaly: Decrease of cortical bone thickness after treatment [10.1530/ENDOABS.63.GP111]


We have observed CD161 expression in some cases of T-cell prolymphocytic leukemia (T-PLL) and found it to be useful in follow-up and detection of disease after treatment.

CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up. [10.1093/ajcp/aqz060]


Quantitative real‐time polymerase chain reaction and cell‐substrate adhesion assays were used to measure alterations in fibrosis‐related molecule expression and the cell adhesion ability of frozen shoulder SCFs after treatment with range concentrations of sCT.

Investigation of salmon calcitonin in regulating fibrosis‐related molecule production and cell‐substrate adhesion in frozen shoulder synovial/capsular fibroblasts [10.1002/jor.24571]


In this study, we found that the Mtb sRNA Mcr11, which is expressed at high levels in slowly replicating Mtb and during mouse infection, regulates expression of several target genes involved in central metabolism.

Small RNA Mcr11 regulates genes involved in the central metabolism of Mycobacterium tuberculosis and requires 3’ sequence along with the transcription factor AbmR for stable expression [10.1101/616912]


DESIGN A total of 233 cases of colorectal carcinoma diagnosed in our health system were retrospectively analyzed and routine H&E stained slides of these cases were collected.

Tumor budding in colorectal carcinoma: An institutional interobserver reliability and prognostic study of colorectal adenocarcinoma cases. [10.1016/j.anndiagpath.2019.151420]


Conclusion: Our study shows that COX-2 over expression in colorectal carcinoma patients is closely associated with clinico-pathological parameters and is more pronounced in males versus females.

Over-Expression of Cyclooxygenase-2 in Colorectal Cancer Patients [10.31557/APJCP.2019.20.6.1675]


Materials and Methods: The cytotoxic effect was investigated with Sulphorhodamine B method against Colo205 (human colon carcinoma), A549 (human non-small cell lung cancer) cell lines, and antioxidant activity tested with 1,1-diphenyl-2-picrylhydrazyl, 2,2'-azino-bis 3-ethylbenzothiazoline-6-sulphonic acid scavenging tests, and β-carotene/linoleic acid co-oxidation test.

Bioactivity-guided isolation of cytotoxic and antioxidant phytochemicals from four Cousinia species from stenocephala bunge section [10.4103/pm.pm_487_18]


The present study aimed to clarify the mechanism underlying abnormal CD146 expression in human pulmonary large cell neuroendocrine carcinoma (LCNEC) cell lines (NCI-H460 and NCI-H810).

CD146 promotes migration and proliferation in pulmonary large cell neuroendocrine carcinoma cell lines [10.3892/ol.2018.9830]


dCPD is widely expressed throughout the nervous system, including peptidergic neurons in the mushroom body and neuroendocrine cells expressing adipokinetic hormone.

Drosophila carboxypeptidase D (SILVER) is a key enzyme in neuropeptide processing required to maintain locomotor activity levels and survival rate [10.1101/551853]


e15693Background: Resection of the primary tumor in metastatic neuroendocrine tumor (NET) is controversial.

Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET). [10.1200/JCO.2019.37.15_SUPPL.E15693]


015) and exhibited diagnostic potential.

Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinoma [10.3892/ol.2018.9863]


The study aimed to investigate the diagnostic efficacy of real‐time nCLE for gastric SELs and to assess the technical aspects and safety of real‐time nCLE.

In vivo real‐time diagnosis of endoscopic ultrasound‐guided needle‐based confocal laser endomicroscopy in gastric subepithelial lesions [10.1111/jgh.14863]


Therefore, proper feature extraction from vibration signals is necessary to develop a reliable diagnostic system for condition monitoring of induction motors.

Autocorrelation Based Feature Extraction for Bearing Fault Detection in Induction Motors [10.1109/UPCON47278.2019.8980025]


Although the end product is most commonly humoral immunity, the rapid proliferation and somatic mutation of the B cell receptor also results in oncogenic mutations that cause B cell malignancies including plasma cell neoplasms such as multiple myeloma.

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma [10.3389/fimmu.2019.01121]


Patients with myeloproliferative neoplasms (MPNs) are faced with high disease-related symptom burden and quality of life (QoL) decrements.

Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? [10.1080/10428194.2018.1480768]


Nevus Sebaceous of Jadasson (SNJ) has been reported with various coexisting benign and rarely with malignant neoplasms.

Naevus Sebaceous with Tumour of the Follicular Infundibulum, Trichilemmoma, Desmoplastic Trichilemmoma, Apocrine Adenoma and Syringocystadenoma Papilliferum: Report of a Case [10.31579/2578-8949/046]


But in breast tumors and in tumor cell lines, methyl tags cover the promoter region of the NDRG4-encoding gene, resulting in reduced protein expression, increased tumor size, elevated cell mobility and other molecular features indicative of a more aggressive disease state.

NDRG4 promoter hypermethylation is a mechanistic biomarker associated with metastatic progression in breast cancer patients [10.1038/s41523-019-0106-x]


In this study, the anti-angiogenic effects of Semaphorin (SEMA) 3F, which has frequently been reported to have tumor suppressive properties, on a chick chorioallantoic membrane model as well as in vitro cell-cell interactions were investigated and comparatively assessed using anti-VEGF antibody.

Inhibitory effects of Semaphorin 3F as an alternative candidate to anti-VEGF monoclonal antibody on angiogenesis [10.1007/s11626-019-00392-x]


Here, we show that epigenetic silencing of NDRG4 modulates integrin signaling by assembling β1-integrins into large punctate clusters at the leading edge of tumor cells to promote an “adhesive switch,” decreasing cell adhesion to fibronectin and increasing cell adhesion and migration towards vitronectin, an important component of human lymph nodes.

NDRG4 promoter hypermethylation is a mechanistic biomarker associated with metastatic progression in breast cancer patients [10.1038/s41523-019-0106-x]


Our previous report revealed that atrophic change of GC, glomeruloid vascular proliferation, and abnormal proliferation of follicular dendritic cells are more prominent in iMCD with TAFRO (TAFRO+) in comparison to iMCD without TAFRO (TAFRO-).

The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome. [10.1016/j.prp.2019.152563]


We present a case of a 43-year-old man with accidental finding of asymptomatic fourth pouch cyst and fistula following follicular thyroid cancer surgery.

Spontaneous Resolution of Fourth Branchial Fistula Following Thyroid Surgery: Case Report [10.1007/s12070-019-01588-z]


Six months ago a patient addressed to our clinic who underwent surgical treatment for a papillary carcinoma (follicular variant) of the thyroid gland in the volume of thyroidectomy with pre-tracheal lymphodissection and subsequent course of radioiodine therapy at the place of residence.

Medullary thyroid cancer. Returning to the need to determine the preoperative basal calcitonin level in patients with thyroid nodular pathology [10.14341/SERG10044]


The insights deduced in the paper are primarily based on 42 articles selected for critical review and analysis in the domain of currency futures and hence should be interpreted only as key concerns in the area.

The Effects of Introducing Currency Futures on Spot Exchange Rates – A Review of Related Literature [10.18843/ijms/v6i1(6)/01]


Methods and analysis This systematic review protocol is consistent with the methodology recommended by the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols and the Cochrane handbook for systematic reviews of interventions.

Effectiveness of interventions to improve hand motor function in individuals with moderate to severe stroke: a systematic review protocol [10.1136/bmjopen-2019-032413]


Frailty screening can help prioritize targeted frailty-tailored treatments, such as nutrition, early mobility and medication review, for these vulnerable patients to improve clinical outcomes.

The impact of frailty on prolonged hospitalization and mortality in elderly inpatients in Vietnam: a comparison between the frailty phenotype and the Reported Edmonton Frail Scale [10.2147/CIA.S189122]